Bengaluru: MedGenome Labs– the leader in clinical data-driven genetic diagnostics and drug discovery research in India, has developed ‘SPIT SEQ’, the first Whole Genome Sequencing based test that can provide a detailed analysis of every single mutation present in any tuberculosis bacteria causing drug resistance-directly from the sputum. This break-through will enable a doctor to quickly and accurately prescribe the most effective drug to a tuberculosis patient without a trial and error process, followed currently that takes a month.
India has the largest number of multi drug resistant (MDR-TB) TB cases. SPIT SEQ can be a boon for TB patients, clinicians and healthcare agencies to achieve India’s Sustainable Development Goal (SDG) of elimination TB by 2025. The test is based on whole genome sequencing of mycobacterium tuberculosis (MTB), the TB causing bacteria, to assess the mutations in bacteria’s genome and allows a clinician to determine which drugs will work for a patient.
This test has been validated with over 100 samples where it recorded with 100% sensitivity and 98.04 % specificity when compared with Line Probe Assay (LPA). 50 out of those samples were in association with P.D. Hinduja Hospital and Medical Research Centre, Mumbai. A manuscript is under review for publication. Typically, the process of analyzing the drug resistance is very long which delays treatment for MDR-TB patient. Here as well, the current expertise allows testing resistance only on 4 drugs hence the patient had to wait until testing on all possible drug concluded. In such a situation, where long turn-around diagnosis time, repeated testing led to multiple changes in the course of treatment along the way.
Dr VL Ramprasad, COO, MedGenome labs explaining the efficacy of SPIT SEQ a world class test for TB to test every possible mutation.